{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:10:32Z","timestamp":1790647832093,"version":"4.1.0"},"reference-count":43,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.3892\/or.2015.3910","type":"journal-article","created":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T09:06:50Z","timestamp":1428570410000},"page":"2737-2745","source":"Crossref","is-referenced-by-count":51,"title":["Orally active \u03b1v\u03b23 integrin inhibitor MK-0429 reduces melanoma metastasis"],"prefix":"10.3892","volume":"33","author":[{"given":"MAUREEN","family":"PICKARSKI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALEXA","family":"GLEASON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BOHUMIL","family":"BEDNAR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LE T.","family":"DUONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,4,9]]},"reference":[{"key":"key20180107213617_b1-or-33-06-2737","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"key20180107213617_b2-or-33-06-2737","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4065\/81.4.500","article-title":"Cutaneous malignant melanoma","volume":"81","author":"Cummins","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"key20180107213617_b3-or-33-06-2737","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1345\/aph.1R614","article-title":"Novel targets in the treatment of advanced melanoma: New first-line treatment options","volume":"47","author":"Culos","year":"2013","journal-title":"Ann Pharmacother"},{"key":"key20180107213617_b4-or-33-06-2737","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/09546634.2013.813897","article-title":"Severe adverse events from the treatment of advanced melanoma: A systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2","volume":"25","author":"Ma","year":"2014","journal-title":"J Dermatolog Treat"},{"key":"key20180107213617_b5-or-33-06-2737","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10555-005-1572-1","article-title":"Integrin signaling in malignant melanoma","volume":"24","author":"Kuphal","year":"2005","journal-title":"Cancer Metastasis Rev"},{"key":"key20180107213617_b6-or-33-06-2737","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/bjc.1998.85","article-title":"Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas","volume":"77","author":"Marshall","year":"1998","journal-title":"Br J Cancer"},{"key":"key20180107213617_b7-or-33-06-2737","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF00690295","article-title":"The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis","volume":"14","author":"Nip","year":"1995","journal-title":"Cancer Metastasis Rev"},{"key":"key20180107213617_b8-or-33-06-2737","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1023\/A:1006304806799","article-title":"Cell adhesion molecules in the development and progression of malignant melanoma","volume":"18","author":"Johnson","year":"1999","journal-title":"Cancer Metastasis Rev"},{"key":"key20180107213617_b9-or-33-06-2737","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: Biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"key20180107213617_b10-or-33-06-2737","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/sj.bjc.6601576","article-title":"Integrins: Roles in cancer development and as treatment targets","volume":"90","author":"Jin","year":"2004","journal-title":"Br J Cancer"},{"key":"key20180107213617_b11-or-33-06-2737","first-page":"2724","article-title":"Integrin \u03b1v\u03b23 promotes M21 melanoma growth in human skin by regulating tumor cell survival","volume":"59","author":"Petitclerc","year":"1999","journal-title":"Cancer Res"},{"key":"key20180107213617_b12-or-33-06-2737","doi-asserted-by":"crossref","first-page":"29336","DOI":"10.1074\/jbc.M112.341917","article-title":"Protein kinase C\u03b1 (PKC\u03b1) regulates p53 localization and melanoma cell survival downstream of integrin \u03b1v in three-dimensional collagen and in vivo","volume":"287","author":"Smith","year":"2012","journal-title":"J Biol Chem"},{"key":"key20180107213617_b13-or-33-06-2737","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1083\/jcb.200404018","article-title":"Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen","volume":"167","author":"Bao","year":"2004","journal-title":"J Cell Biol"},{"key":"key20180107213617_b14-or-33-06-2737","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1357-2725(96)00155-0","article-title":"The alpha v beta 3 integrin \u2018vitronectin receptor\u2019","volume":"29","author":"Horton","year":"1997","journal-title":"Int J Biochem Cell Biol"},{"key":"key20180107213617_b15-or-33-06-2737","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-4064-6","volume-title":"Integrin-Ligand Interaction","author":"Eble","year":"1997"},{"key":"key20180107213617_b16-or-33-06-2737","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0002-9440(10)65730-6","article-title":"Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma","volume":"153","author":"Hsu","year":"1998","journal-title":"Am J Pathol"},{"key":"key20180107213617_b17-or-33-06-2737","first-page":"2824","article-title":"Multiple roles for platelet GPIIb\/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis","volume":"62","author":"Trikha","year":"2002","journal-title":"Cancer Res"},{"key":"key20180107213617_b18-or-33-06-2737","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.toxicon.2007.07.016","article-title":"Effect of RGD-disintegrins on melanoma cell growth and metastasis: Involvement of the actin cytoskeleton, FAK and c-Fos","volume":"50","author":"Oliva","year":"2007","journal-title":"Toxicon"},{"key":"key20180107213617_b19-or-33-06-2737","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/bbrc.2000.3130","article-title":"Suppressive mechanism of salmosin, a novel disintegrin in B16 melanoma cell metastasis","volume":"275","author":"Kang","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107213617_b20-or-33-06-2737","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1021\/jm030306r","article-title":"Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis","volume":"46","author":"Hutchinson","year":"2003","journal-title":"J Med Chem"},{"key":"key20180107213617_b21-or-33-06-2737","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1210\/jc.2004-2126","article-title":"Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women","volume":"90","author":"Murphy","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"key20180107213617_b22-or-33-06-2737","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1743-7563.2009.01266.x","article-title":"Evaluation of the safety, pharmacokinetics and treatment effects of an \u03b1v\u03b23 integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases","volume":"6","author":"Rosenthal","year":"2010","journal-title":"Asia Pac J Clin Oncol"},{"key":"key20180107213617_b23-or-33-06-2737","doi-asserted-by":"crossref","first-page":"29380","DOI":"10.1074\/jbc.272.46.29380","article-title":"The alphavbeta3 integrin regulates alpha5beta1-mediated cell migration toward fibronectin","volume":"272","author":"Simon","year":"1997","journal-title":"J Biol Chem"},{"key":"key20180107213617_b24-or-33-06-2737","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/mol.52.2.227","article-title":"Arginine-glycine-aspartic acid mimics can identify a transitional activation state of recombinant alphaIIb beta3 in human embryonic kidney 293 cells","volume":"52","author":"Abraham","year":"1997","journal-title":"Mol Pharmacol"},{"key":"key20180107213617_b25-or-33-06-2737","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11307-009-0279-z","article-title":"Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT)","volume":"12","author":"Kossodo","year":"2010","journal-title":"Mol Imaging Biol"},{"key":"key20180107213617_b26-or-33-06-2737","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/1471-2474-12-197","article-title":"Molecular changes in articular cartilage and subchondral bone in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis","volume":"12","author":"Pickarski","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"key":"key20180107213617_b27-or-33-06-2737","first-page":"218","article-title":"Biological behavior of malignant melanoma cells correlated to their survival in vivo","volume":"35","author":"Fidler","year":"1975","journal-title":"Cancer Res"},{"key":"key20180107213617_b28-or-33-06-2737","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.887927","article-title":"Metastasis results from preexisting variant cells within a malignant tumor","volume":"197","author":"Fidler","year":"1977","journal-title":"Science"},{"key":"key20180107213617_b29-or-33-06-2737","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1091\/mbc.E04-12-1082","article-title":"Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression","volume":"16","author":"Cowden Dahl","year":"2005","journal-title":"Mol Biol Cell"},{"key":"key20180107213617_b30-or-33-06-2737","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00441-009-0834-6","article-title":"Integrins","volume":"339","author":"Barczyk","year":"2010","journal-title":"Cell Tissue Res"},{"key":"key20180107213617_b31-or-33-06-2737","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1126\/science.285.5430.1028","article-title":"Integrin signaling","volume":"285","author":"Giancotti","year":"1999","journal-title":"Science"},{"key":"key20180107213617_b32-or-33-06-2737","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0046-8177(99)90202-2","article-title":"Progression-related expression of beta3 integrin in melanomas and nevi","volume":"30","author":"Van Belle","year":"1999","journal-title":"Hum Pathol"},{"key":"key20180107213617_b33-or-33-06-2737","first-page":"6757","article-title":"Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progres\u00adsion","volume":"50","author":"Albelda","year":"1990","journal-title":"Cancer Res"},{"key":"key20180107213617_b34-or-33-06-2737","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0959-8049(96)00381-4","article-title":"Role of integrins in angiogenesis","volume":"32A","author":"Brooks","year":"1996","journal-title":"Eur J Cancer"},{"key":"key20180107213617_b35-or-33-06-2737","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0092-8674(00)81235-0","article-title":"Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3","volume":"85","author":"Brooks","year":"1996","journal-title":"Cell"},{"key":"key20180107213617_b36-or-33-06-2737","doi-asserted-by":"crossref","first-page":"135164","DOI":"10.1155\/2013\/135164","article-title":"Integrin signaling as a cancer drug target","volume":"2013","author":"Danen","year":"2013","journal-title":"ISRN Cell Biol"},{"key":"key20180107213617_b37-or-33-06-2737","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1200\/JCO.2008.16.7510","article-title":"Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme","volume":"26","author":"Reardon","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180107213617_b38-or-33-06-2737","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/CMR.0b013e32835312e4","article-title":"A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma","volume":"22","author":"Kim","year":"2012","journal-title":"Melanoma Res"},{"key":"key20180107213617_b39-or-33-06-2737","first-page":"3056","article-title":"Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3","volume":"6","author":"Gutheil","year":"2000","journal-title":"Clin Cancer Res"},{"key":"key20180107213617_b40-or-33-06-2737","doi-asserted-by":"crossref","first-page":"7851","DOI":"10.1158\/1078-0432.CCR-05-0262","article-title":"Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion","volume":"11","author":"Mcneel","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20180107213617_b41-or-33-06-2737","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/cncr.24821","article-title":"Etaracizumab Melanoma Study Group: A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin \u03b1v\u03b23, \u00b1 dacarbazine in patients with stage IV metastatic melanoma","volume":"116","author":"Hersey","year":"2010","journal-title":"Cancer"},{"key":"key20180107213617_b42-or-33-06-2737","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm.1941","article-title":"Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors","volume":"15","author":"Reynolds","year":"2009","journal-title":"Nat Med"},{"key":"key20180107213617_b43-or-33-06-2737","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.molonc.2014.07.027","article-title":"No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients","volume":"8","author":"Girotti","year":"2014","journal-title":"Mol Oncol"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2015.3910\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T05:11:12Z","timestamp":1566537072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2015.3910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,9]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,4,9]]},"published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.3892\/or.2015.3910"],"URL":"https:\/\/doi.org\/10.3892\/or.2015.3910","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,9]]}}}